Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Upadacitinib effectively treated severe atopic dermatitis, vitiligo, and alopecia areata in one patient.

Upadacitinib effectively treats psoriasiform eczema and some related conditions.

Adalimumab can cause complete hair loss in rare cases.

Ruxolitinib reduced inflammation and improved symptoms in APECED patients but may cause anemia and weight gain.

Tralokinumab successfully treated alopecia areata in a patient with atopic dermatitis.

A man with Acrodermatitis continua did not get better with etanercept treatment, and his condition worsened, suggesting treatment effectiveness may vary by genetics and race.

Bimekizumab quickly improves psoriasis symptoms and skin at the molecular level.

TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.

Tildrakizumab showed limited effectiveness in treating chronic alopecia areata in a small group of patients.

Adalimumab improved folliculitis decalvans in most patients.

TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.

Upadacitinib may help treat difficult cases of systemic lupus erythematosus.

Tofacitinib treatment significantly improved a patient's psoriasis, psoriatic arthritis, and alopecia universalis.

Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.

IL-12/23 inhibitors are more effective and have fewer common side effects than anti-TNF alpha for treating psoriasis.

Tofacitinib is a promising treatment for children with rheumatic diseases.

Tofacitinib treatment for hair loss may worsen acne.

Upadacitinib significantly improved a man's severe scalp condition when other treatments failed.

A woman with a drug allergy to anakinra was successfully desensitized, allowing her to continue treatment without allergic reactions.

A patient with PPP had rare skin reactions to adalimumab, which improved after stopping smoking and continuing acitretin.

JAK inhibitors may help improve symptoms in adults with APECED.

TAK-279 effectively reduces psoriasis symptoms and is safe.

Tralokinumab may help improve symptoms of atopic dermatitis and alopecia areata.

Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.

Dupilumab improved severe atopic dermatitis in a patient who didn't respond to other treatments.

Janus Kinase inhibitors effectively induce remission in Ulcerative Colitis with an acceptable safety profile.

Tofacitinib, a hair regrowth treatment, may worsen acne.

A woman with severe hair loss was successfully treated with the drug adalimumab.

Tofacitinib may be safe and effective for treating certain skin conditions in children.

JAK1 inhibitor may effectively treat alopecia areata when TNF-α inhibitors and corticosteroids fail.